New drug for advanced cervical cancer after PD-1 therapy stops working
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called QL1706 for people with cervical cancer that has spread and no longer responds to PD-1/PD-L1 therapy. It may offer a new treatment option if you have tried this type of immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has spread or come back and no longer responds to PD-1 or PD-L1 therapy.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 months.
- You have at least one tumor that can be measured on scans (at least 10 mm for non-lymph node tumors or 15 mm for lymph node tumors).
- Your blood counts and organ function are within certain safe limits (your doctor will check this).
- If you could become pregnant, you agree to use effective birth control during and for 180 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests a new treatment called QL1706 for people with cervical cancer that has come back or spread and has not responded to platinum-based chemotherapy. It aims to see if QL1706 can help shrink tumors and improve outcomes.
This trial tests a new treatment (QL706) combined with chemotherapy, with or without bevacizumab, for cervical cancer that has stopped responding to previous immunotherapy. It aims to find a better option for patients whose disease has progressed after anti-PD-1/PD-L1 therapy.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.